Applications of high-resolution MS in bioanalysis

Bioanalysis

Volumn 5, Issue 10, 2013, Pages 1269-1276

  Huang, Mike Qingtao ^a   Lin, Zhongping ^b   Weng, Naidong ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Frontage Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; BINDING AFFINITY; BINDING ASSAY; BIOASSAY; BIOCHEMICAL COMPOSITION; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PEPTIDE ANALYSIS; PROCESS DEVELOPMENT; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 84878486850     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.100     Document Type: Review

References (50)

1. Maurer HH. Perspectives of liquid chromatography coupled to low-and high-resolution mass spectrometry for screening, identifcation, and quantifcation of drugs in clinical and forensic toxicology. Ther. Drug Monit. 32, 324-327 (2010)
2. Zhu M, Ma L, Zhang D et al. Detection and characterization of metabolites in biological matrices using mass defect fltering of liquid chromatography/high resolution mass spectrometry data. Drug Metab. Dispos. 34, 1722-1733 (2006).
3. Zhu M, Ma L, Zhang H, Humphreys WG. Detection and structural characterization of glutathione-trapped reactivemetabolites using liquid chromatography-high-resolution mass spectrometry and mass defect fltering. Anal. Chem. 79, 8333-8341 (2007).
4. Ma S, Zhu M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem. Biol. Interact. 179, 25-37 (2009).
5. Zhang H, Zhang D, Ray K, Zhu M. Mass defect flter technique and its applications to drug metabolite identifcation by high-resolution mass spectrometry. J. Mass Spectrom. 44, 999-1016 (2009).
6. Jemal M. High-throughput quantitative bioanalysis by LC-MS/MS. Biomed. Chromatogr. 14, 422-429 (2000).
7. Henion J, Brewer E, Rule G. Preparation for LC-MS/MS: analyzing biological and environmental samples-knowing the basic requirements and the big picture of an LC-MS system can ensure success in most instances. Anal. Chem. 70, 650A-656A (1998).
8. Weng N, Chen YL, Shou W, Jiang X. Importance of injection solution composition for LC-MS/MS methods. J. Pharm. Biomed. Anal. 26, 753-767 (2001).
9. Korfmacher W. Principles and applications of LC-MS in new drug discovery. Drug Discov. Today 10, 1357-1367 (2005).
10. Zhou S, Song Q, Tang Y, Weng N. Critical review of development, validation, and transfer for high throughput bioanalytical LC-MS/MS methods. Curr. Pharm. Anal. 1, 3-14 (2005).
11. Korfmacher W. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalytical procedures. Bioanalysis 3, 1169-1171 (2011).
12. Josephs JL. HRMS: current usage, future directions and the promise of integration with unifed data streams suited to post-acquisition mining. Bioanalysis 4, 471-476 (2012).
13. Ma S, Chowdhury SK. Application of LC-high-resolution MS with 'intelligent' data mining tools for screening reactive drug metabolites. Bioanalysis 4, 501-510 (2012).
14. Campbell JL, Le Blanc JC. Using high-resolution quadrupole TOF technology in DMPK analyses. Bioanalysis 4, 487-500 (2012).
15. Miller VP. SPE-MS analysis of absorption, distribution, metabolism and excretion assays: a tool to increase throughput and streamline workfow. Bioanalysis 4, 111-1121 (2012).
16. Ramanathan R, Korfmacher W. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis 4, 467-469 (2012).
17. ® 5600). Anal. Chem. 83, 5442-5446 (2011).
18. Junot C, Madalinski G, Tabet JC, Ezan E. Fourier transform mass spectrometry for metabolome analysis. Analyst 135, 2203-2219 (2010).
19. Makarov A, Scigelova M. Coupling liquid chromatography to Orbitrap mass spectrometry. J. Chromatogr. A 1217, 3938-3945 (2010).
20. Scigelova M, Makarov A. Advances in bioanalytical LC-MS using the Orbitrap mass analyzer. Bioanalysis 1, 741-754 (2009).
21. Zhang NR, Yu S, Tiller P, Yeh S, Mahan E, Emary WB. Quantitation of small molecules using high-resolution accurate mass spectrometers-a different approach for analysis of biological samples. Rapid Commun. Mass Spectrom. 23, 1085-1094 (2009).
22. Bateman KP, Kellmann M, Muenster H, Papp R, Taylorc L. Quantitative-qualitative data acquisition using a benchtop Orbitrap mass spectrometer. J. Am. Soc. Mass Spectrom. 20, 1441-1450 (2009).
23. Kaufmann A, Butcher P, Maden K, Walker S, Widmer M. Quantitative and confrmative performance of liquid chromatography coupled to high-resolution mass spectrometry compared to tandem mass spectrometry. Rapid Commun. Mass Spectrom. 25, 979-992 (2011).
24. Kaufmann A, Widmer M, Maden K. Post-interface signal suppression, a phenomenon observed in a single-stage Orbitrap mass spectrometer coupled to an electrospray interfaced liquid chromatograph. Rapid Commun. Mass Spectrom. 24, 2162-2170 (2010).
25. Xia YQ, Lau J, Olah T, Jemal M. Targeted Quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profle modes. Rapid Commun. Mass Spectrom. 25, 2863-2878 (2011).
26. Wei C, Grace JE, Zvyaga TA, Drexler DM. Utility of high-resolution accurate MS to eliminate interferences in the bioanalysis of ribavirin and its phosphate metabolites. Bioanalysis 4, 1895-1905 (2012).
27. Ramanathan R, Jemal M, Ramagiri S et al. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J. Mass Spectrom. 46, 595-601 (2011).
28. Ranasinghe A, Ramanathan R, Jemal M et al. Integrated quantitative and qualitative workfow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. Bioanalysis 4, 511-528 (2012).
29. Zhang J, Maloney J, Drexler DM et al. Cassette incubation followed by bioanalysis using high-resolution MS for in vitro ADME screening assays. Bioanalysis 4, 581-593 (2012).
30. Fung EN, Xia YQ, Aubry AF, Zeng J, Olah T, Jemal M. Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma. J. Chromatogr. B. 879, 2919-2927 (2011).
31. Han B, Copeland M, Geiser AG et al. Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity. J. Proteome Res. 6, 4218-4229 (2007).
32. Ji C, Sadagopan N, Zhang Y, Lepsy C. A universal strategy for development of a method for absolute quantifcation of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry. Anal. Chem. 81, 9321-9328 (2009).
33. Hoofnagle AN, Wener MH. The fundamental faws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 347, 3-11 (2009).
34. Wu ST, Ouyang Z, Olah TV, Jemal ML. A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection. Rapid Commun. Mass Spectrom. 25, 281-290 (2011).
35. Plumb RS, Fujimoto G, Mather J et al. Comparison of the quantifcation of a therapeutic protein using nominal and accurate mass MS/MS. Bioanalysis 4, 605-615 (2012).
36. Dillen L, Cools W, Vereyken L et al. Comparison of triple quadrupole and high-resolution TOF-MS for quantifcation of peptides. Bioanalysis 4, 565-579 (2012).
37. Ramagiri S, Garofolo F. Large molecule bioanalysis using Q-TOF without predigestion and its data processing challenges. Bioanalysis 4, 529-540 (2012).
38. Ruan Q, Ji QC, Arnold ME, Humphreys WG, Zhu M. Strategy and its implications of protein bioanalysis utilizing high-resolution mass spectrometric detection of intact protein. Anal. Chem. 83, 8937-8944 (2011).
39. Ji QC, Rodila R, Gage EM, EL-Shourbagy TA. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Anal. Chem. 75, 7008-7014 (2003).
40. Ji QC, Rodila R, Morgan S, Humerickhouse RA, EL-Shourbagy TA. Investigation of the immunogenicity of a protein drug using equilibrium dialysis and liquid chromatography tandem mass spectrometry detection. Anal. Chem. 77, 5529-5533 (2005).
41. Gucinski AC, Boyne II MT. Evaluation of intact mass spectrometry for the quantitative analysis of protein therapeutics. Anal. Chem. 84, 8045-8051 (2011).
42. Jian W, Edom RW, Wang D, Weng N, Zhang S. Relative quantitation of glycoisoforms of intact apolipoprotein C3 in human plasma by liquid chromatography-high-resolution mass spectrometry. Anal. Chem. 85, 2867-2874 (2013).
43. Lin ZJ, Li W, Dai G. Application of LC-MS for quantitative analysis and metabolite identifcation of therapeutic oligonucleotides. J. Pharm. Biomed. Anal. 44, 330-341 (2007).
44. Hopfgartner G, Varesio E. New approaches for quantitative analysis in biological fuids using mass spectrometric detection. Trends Anal. Chem. 24, 583-589 (2005).
45. Jian W, Edom R, Weng N, Zannikos P, Zhang Z, Wang H. Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma. J. Chromatogr. B 878, 1687-1699 (2010).
46. Jian W, Edom RW, Weng N. Important considerations for quantitation of biomarkers using liquid chromatography and mass spectrometry (LC-MS), Bioanalysis 4, 2431-2434 (2012).
47. Jemal M, Xia YQ. LC-MS development strategies for quantitative bioanalysis, Curr. Drug Metab. 7, 491-502 (2006).
48. Gao S, Zhang ZP, Karnes HT. Sensitivity enhancement in liquid chromatography/atmospheric pressure ionization mass spectrometry using derivatization and mobile phase additives, J. Chromatogr. B 825, 98-110 (2005).
49. Zhu LS, Lapko VN, Lee JW et al. A General approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20, 3421-3426 (2006).
50. Li W, Li YH, Li AC, Zhou S, Weng N. Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry-experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity. J. Chromatogr. B 825, 223-232 (2005).